Debt-to-equity of BioNexus Gene Lab Corp from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BioNexus Gene Lab Corp quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • BioNexus Gene Lab Corp Debt-to-equity for the quarter ending 30 Sep 2025 was 21%, a 20% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

BioNexus Gene Lab Corp Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 21% +4% +20% 30 Sep 2025
Q2 2025 22% +4% +21% 30 Jun 2025
Q1 2025 20% -1% -6.5% 31 Mar 2025
Q4 2024 19% -4% -15% 31 Dec 2024
Q3 2024 18% -9% -33% 30 Sep 2024
Q2 2024 18% -10% -35% 30 Jun 2024
Q1 2024 21% -4% -16% 31 Mar 2024
Q4 2023 23% -3% -12% 31 Dec 2023
Q3 2023 27% 0% 0% 30 Sep 2023
Q2 2023 28% -3% -8.6% 30 Jun 2023
Q1 2023 25% -9% -27% 31 Mar 2023
Q4 2022 26% -13% -33% 31 Dec 2022
Q3 2022 27% -17% -39% 30 Sep 2022
Q2 2022 31% -4% -10% 30 Jun 2022
Q1 2022 35% +9% +36% 31 Mar 2022
Q4 2021 39% +25% +170% 31 Dec 2021
Q3 2021 44% +42% +2246% 30 Sep 2021
Q2 2021 34% +32% +1259% 30 Jun 2021
Q1 2021 26% +21% +526% 31 Mar 2021
Q4 2020 14% +6% +72% 31 Dec 2020
Q3 2020 2% -6% -77% 30 Sep 2020
Q2 2020 3% 30 Jun 2020
Q1 2020 4% 31 Mar 2020
Q4 2019 8% 31 Dec 2019
Q3 2019 8% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.